Baxter International, Inc. (BAX)

Defensive large cap

Goldman Sachs owns a massive quantity

2009 World's Most Ethical Companies:
http://ethisphere.com/wme2009/

PEG = 1.05

Baxter is currently trading near its 52 week low yet its current earnings estimates are very strong. Despite a low beta ratio, this stock has high earning potential in the next 6 months. News reports suggest that Baxter and another drug manufacturer will be commissioned to produced this winters swine flu vaccine which should provide another boost to this companies already strong financials.

Because this is a solid company with excellent growth over the longhaul not a quick mover but a steady dividend producer.

Using a proprietary system I've created Baxter comes out as having long term potential.

this seems to be the consensus

This recommendation is founded on possible pandemic from new swine flu and Baxter's advanced vaccine capabilities.

However, BAX is one of the vaccine developers with newer technology that does not utilize chicken eggs and can provide initial test batches in half the time (~ 16 weeks) from government providing reference sample.

I expect that BAX and the rival will be given dual source contracts to deliver vaccine units for the U.S. population. This will add several hundred million to BAX's revenue likely at better margins than traditional vaccine programs.

Coincidentally, Baxter recently received negative publicity regarding the fact that one of its labs accidentally mixing avian flu with normal human flu which could have led to more dangerous strain if not caught. Such information is likely baked into the stock's price or disregarded by the market.

Healthcare bear hedge. May even be able to run with the bulls.

comprehensive biopharm pick, several income sources

oldvolvoguy pick

For difficulte times, defensive stocks. Baxter is one of them. ROE of 30%, operatin margin of 21% and a current ratio os 2 shows that, Baxter is not only a defensive bet as a really profitable company.

Got a stable rating today, that is a stand out

Gaming the system again: banking a positive score (12.31), while lowering my cost basis form $53 to $52.

Needless to say, I remain positive on this one.

Held in mutual fund, real money.

Solid company in one of the few industries that does not have much downside. They just keep plugging along and will outperform over the next year or two.

Just because

The Company provides medical products and services. Its medical devices, pharmaceuticals and biotechnology assists healthcare professionals and their patients in the treatment of complex medical conditions